Posted on 04/05/2020 1:06:32 AM PDT by cba123
Sort of a small test, but noteworthy in being just of early patients, and it (once again) showed very positive results.
https://www.contagionlive.com/news/results-from-a-controlled-trial-of-hydroxychloroquine-for-covid19
https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf
Excerpts:
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study Running title: Hydroxychloroquine-Azithromycin and COVID-19
Abstract We need an effective treatment to cure COVID-19 patients and to decrease the virus carriage duration. In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin we noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year-old patient still in intensive care unit. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5.
This allowed patients to rapidly de discharge from highly contagious wards with a mean length of stay of five days. We believe other teams should urgently evaluate this cost-effective therapeutic strategy, to both avoid the spread of the disease and treat patients as soon as possible before severe respiratory irreversible complications take hold
Three in vitro studies have demonstrated that chloroquine phosphate inhibits SARS-CoV-2 (8;9) and two have demonstrated that hydroxychloroquine sulfate inhibits SARS-CoV-2 (8-10).
Other studies have pointed out that drug repurposing may identify approved drugs that could be useful for the treatment of this disease including, notably, chloroquine, hydroxychloroquine and azithromycin, as well as anti-diabetics such as metformin, angiotensin receptor inhibitors such as sartans, or statins such as simvastatin (11).
In addition, chloroquine has demonstrated its efficacy in Chinese COVID-19 patients in clinical trials by reducing fever, improving CT imaging, and delaying disease progression (12-14), leading Chinese experts to recommend chloroquine-based treatment (500 mg twice per day for ten days) as a first line-treatment for mild, moderate and severe cases of COVID-19 (15).
. . .COVID treatment Patients with no contraindications (Supplementary document 1) were offered a combination of 200 mg of oral hydroxychloroquine sulfate, three times per day for ten days combined with azithromycin (500mg on D1 followed by 250mg per day for the next four days). For patients with pneumonia and NEWS score≥5, a broad spectrum antibiotic (ceftriaxone) was added to hydroxychloroquine and azithromycin. Twelve-lead electrocardiograms (ECG) were performed on each patient before treatment and two days after treatment began. All ECGs were reviewed by senior cardiologists. The treatment was either not started or discontinued when the QTc (Bazett’s formula) was > 500 ms and the risk-benefit ratio was estimated to be between 460 and 500 ms. The treatment was not started when the ECG showed patterns suggesting a channelopathy and the risk-benefit ratio was discussed when it showed other significant abnormalities (i.e., pathological Q waves, left ventricular hypertrophy, left bundle branch block). In addition, any drug potentially prolonging the QT interval was discontinued during treatment. Symptomatic treatments, including oxygen, were added when needed. An ionogram and verification of serum potassium levels in particular, was systematically performed upon admission. When needed, standard blood chemistry was checked.
ResultsDemographics and patient status at admission (Tables 1 and 2) A total of 80 patients with confirmed COVID-19 were hospitalised at the Méditerranée Infection University Hospital Institute (N=77) and at a temporary COVID-19 unit (N=3) with dates of entry from 3–21 March 2020.
All patients who received treatment with hydroxychloroquine and azithromycin (16) for at least three days and who were followed-up for at least six days were included in this analysis. The median age of patients was 52 years (ranging from 18 to 88 years) with a M/F sex ratio of 1.1. 57.5% of these patients had at least one chronic condition known to be a risk factor for the severe form of COVID-19 with hypertension, diabetes and chronic respiratory disease being the most frequent.
The time between the onset of symptoms and hospitalisation was on average five days, with the longest time being 17 days. 53.8% of patients presented with LRTI symptoms and 41.2% with URTI symptoms. Only 15% of patients were febrile. Four patients were asymptomatic carriers. The majority of patients had a low NEWS score (92%) and 53.8% of patients had LDCT compatible with pneumonia. The mean PCR Ct value was 23.4. Hydroxychloroquine and azithromycin combined treatment (Table 2 and 3) The mean time between the onset of symptoms and the initiation of treatment was 4.9 days and most patients were treated on the day of admission or on the day after (93.7%). A total of 79/80 patients received treatment on a daily basis throughout the whole study period, which lasted a maximum of ten days. In one patient, the treatment had to be stopped on Day4 because, although it was well tolerated there was a potential risk of interaction with another drug. Adverse events were rare and minor.Clinical course (Table 3)
The majority (65/80, 81.3%) of patients had favourable outcome and were discharged from our unit at the time of writing with low NEWS scores (61/65, 93.8%). Only 15% required oxygen therapy. Three patients were transferred to the ICU, of whom two improved and were then returned to the ID ward. One 74 year-old patient was still in ICU at the time of writing. Finally, one 86 year-old patient who was not transferred to the ICU, died in the ID ward (Supplementary Table 1).
The paper itself notes that other treatments the patients received for all patients were not specified or normalized. So each of these patients in the hcq group or not in the group may have received varying amounts of immunoglobulins...antibiotics...steroids..antivirals.
That really muddies up the waters. Sheds very little light on the definitive role of hcq. Don’t hold any treatment the patient may need but a more rigorous study design would have been better.
The French covid-19 IHU study previously published is an ongoing one. The results are updated daily on their website
https://www.mediterranee-infection.com/covid-19/
Currently they have treated 1,818 covid-19 patients with Hydroxychloroquine and azithromycine. Of that group they state there have been 5 deaths in patients who have received 3 or more days of treatment.
Thank you.
Hm. 5 deaths out of 1,818 patients.
5 deaths out of one hundred is 5%.
5 deaths out of one thousand is .5%
5 deaths out of almost two thousand active patients with this virus.
Perhaps it may be possible to get the life insurance companies to back the use of HQ/Zpac therapy.
The value of hydroxychloroquine is, when the S Spike of the virus binds to the ACE-2 receptor of the cell, it prevents the entry of of the virus into the endozome of the cell. Once in the endozome a chain of actions occurs. By preventing this entry it prevents the endozome from releasing single stranded RNA to be taken up by cytoplasm where it gets translated by the host cell’s rybozomes into the polyprotiens needed for a new virus creation.
Ritonovir is another drug that destroys the virus’s efforts to convert the polyprotiens into the building blocks. It does this by acting as a proteais inhibiter which prevents the acton of the proteases to break down the polyproteins into the usable building blocks for the creation of a new virus.
Five days, 62 patients, and a p-value of .0008. Any large study with early intervention in hospitalized patients should already have very significant results.
(donning my tin foil hat) - This may explain why "Dr." Cuomo is only authorizing it to be used on patients who are at death's door. This will allow him to proclaim that the treatment is not effective and that the lockdown must continue indefinitely. Also; that President Trump is giving people false hope by advocating this treatment.
Yes, too many variables and combinations.
Trump referenced this yesterday. Apparently once you hit a ventilator your odds drop dramatically.
They don't sound very confident in their results.
"suggest" and "might" sound like someone talking about the danger of global warming.
A doc on Jessie Waters last night, FDA commissioner Dr. Stephen Hahn, said it would take months for Hydrochlorozine to be finished with trials.
Meanwhile, this from the Post:
“An experimental HIV drug that has been used to successfully treat COVID-19 patients is in its second phase of testing with the Food and Drug Administration and could potentially be approved for use in four weeks, its manufacturer says.”
It’s all about Big Pharma. All about Big Pharma.
Fake news at its best...
Video on site is very informative. Dr. Zelenko is still seeing great results and makes a very convincing argument for why all infected people should be on this protocol.
5 out of 2000 is around .25%
Hydroxychloroquine + azothromax/antibiotic + zinc = Gamechanger
Yes. And yes. Thank you.
It is desirable that every potential patient know this information, and request it from their doctor, and if denied, ask why. And then begin to call politicians’ offices.
Perhaps begin with one’s local congressman.
Then Senator. Then one’s governor. Mayors’ secretaries can be helpful. If one happens to know personally any law enforcement officers or EMTs, or nurses, or CNAs, perhaps give them this article and the protocols as well. Persons with elderly relatives. Any persons one knows with autoimmune diseases who may know how to get some more HCQ.
Sublingual zinc supplements can be purchased anywhere. Here are some good sources: www.lef.org.
Tonic water contains HCQ. Vitamin C in large enough doses acts as an antibiotic.
5 out of 2000 is around .25%
Hydroxychloroquine + azothromax/antibiotic + zinc = Gamechanger
_____________________
given early,,, like first symptoms.
What happened to the 1000 person clinical study in NYC that started a week or ten days ago? Are the results too positive to be published?
Norski’s posts #3 & #5 from the French study has fewer variables as to meds.
https://www.freerepublic.com/focus/news/3831876/posts?page=3#3
https://www.freerepublic.com/focus/news/3831876/posts?page=5#5
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.